全文获取类型
收费全文 | 118676篇 |
免费 | 6259篇 |
国内免费 | 149篇 |
专业分类
耳鼻咽喉 | 1786篇 |
儿科学 | 5479篇 |
妇产科学 | 3999篇 |
基础医学 | 16424篇 |
口腔科学 | 2864篇 |
临床医学 | 8581篇 |
内科学 | 22361篇 |
皮肤病学 | 3421篇 |
神经病学 | 9081篇 |
特种医学 | 5092篇 |
外国民族医学 | 32篇 |
外科学 | 19371篇 |
综合类 | 1719篇 |
一般理论 | 29篇 |
预防医学 | 6015篇 |
眼科学 | 3495篇 |
药学 | 8395篇 |
中国医学 | 350篇 |
肿瘤学 | 6590篇 |
出版年
2018年 | 966篇 |
2017年 | 832篇 |
2016年 | 1146篇 |
2015年 | 1294篇 |
2014年 | 1701篇 |
2013年 | 2488篇 |
2012年 | 3330篇 |
2011年 | 3348篇 |
2010年 | 2082篇 |
2009年 | 2017篇 |
2008年 | 3360篇 |
2007年 | 3598篇 |
2006年 | 3758篇 |
2005年 | 3848篇 |
2004年 | 3801篇 |
2003年 | 3638篇 |
2002年 | 3604篇 |
2001年 | 7067篇 |
2000年 | 7020篇 |
1999年 | 5926篇 |
1998年 | 1663篇 |
1997年 | 1583篇 |
1996年 | 1363篇 |
1995年 | 1208篇 |
1994年 | 1110篇 |
1993年 | 1140篇 |
1992年 | 3816篇 |
1991年 | 3617篇 |
1990年 | 3592篇 |
1989年 | 3377篇 |
1988年 | 3023篇 |
1987年 | 2920篇 |
1986年 | 2840篇 |
1985年 | 2649篇 |
1984年 | 1967篇 |
1983年 | 1620篇 |
1982年 | 938篇 |
1981年 | 919篇 |
1980年 | 772篇 |
1979年 | 1837篇 |
1978年 | 1360篇 |
1977年 | 1123篇 |
1976年 | 952篇 |
1975年 | 1189篇 |
1974年 | 1226篇 |
1973年 | 1213篇 |
1972年 | 1052篇 |
1971年 | 992篇 |
1970年 | 899篇 |
1969年 | 793篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
Martin R. Späth Malte P. Bartram Nicolàs Palacio-Escat K. Johanna R. Hoyer Cedric Debes Fatih Demir Christina B. Schroeter Amrei M. Mandel Franziska Grundmann Giuliano Ciarimboli Andreas Beyer Jayachandran N. Kizhakkedathu Susanne Brodesser Heike Göbel Jan U. Becker Thomas Benzing Bernhard Schermer Martin Höhne Markus M. Rinschen 《Kidney international》2019,95(2):333-349
3.
4.
5.
6.
7.
8.
Die Anaesthesiologie - Eine junge Patientin erleidet während der Anlage einer axillären Plexusblockade einen generalisierten Krampfanfall. Die Mechanismen, im Wesentlichen die vermutlich... 相似文献
9.
Stephan Koter Tina U. Cohnert Korbinian B. Hindermayr Jörg Lindenmann Maximilian Brückner Wolfgang K. Oswald Georg Werkgartner Doris Wagner 《Journal of vascular surgery》2019,69(4):1227-1232
Objective
Low psoas muscle area is shown to be an indicator for worse postoperative outcome in patients undergoing vascular surgical. Additionally, it has been associated with longer durations of hospital stay in patients with cancer who undergo surgery and subsequently greater health care costs in Europe and the United States. We sought to evaluate this effect on hospital expenditure for patients undergoing vascular repair in a health care system with universal access.Methods
Skeletal muscle mass was assessed on preoperative abdominal computed tomography scans of patients undergoing open aortic aneurysm repair in a retrospective fashion. The skeletal muscle index (SMI) was used to define low muscle mass. Health care costs were obtained for all patients and the relationship between a low SMI and higher costs was explored using linear regression and cross-sectional analysis.Results
We included 156 patients (81.5% male) with a median age of 72 years undergoing elective surgery for infrarenal abdominal aortic aneurysm in this analysis. The median SMI for patients with low skeletal muscle mass was 53.21 cm2/kg and for patients without, 70.07 cm2/kg. Hospital duration of stay was 2 days longer in patients with low skeletal muscle mass as compared with patients with normal (14 days vs 11 days; P = .001), as was duration of intensive care stay (3 days vs 1 day; P = .01). The median overall hospital costs were €10,460 higher for patients with a low SMI as compared with patients with a normal physical constitution (€53,739 [interquartile range, €45,007-€62,471] vs €43,279 [interquartile range, €39,509-€47,049]; P = .001). After confounder adjustment, a low SMI was associated with a 14.68% cost increase in overall hospital costs, for a cost increase of €6521.Conclusions
Low skeletal muscle mass is independently associated with higher hospital as well as intensive care costs in patients undergoing elective aortic aneurysm repair. Strategies to reduce this risk factor are warranted for these patients. 相似文献10.
Katie Mycock Lin Zhan Gavin Taylor-Stokes Gary Milligan Debanjali Mitra 《Current oncology (Toronto, Ont.)》2021,28(1):678
Background: Palbociclib is a selective cyclin-dependent kinase (CDK) 4/6 inhibitor used in combination with aromatase inhibitors or fulvestrant for patients with hormone receptor-positive (HR+) human epidermal growth factor receptor 2 (HER2)-negative advanced/metastatic breast cancer (ABC/MBC). Palbociclib was the first CDK 4/6 inhibitor approved for HR+/HER2− ABC/MBC treatment in Canada in combination with letrozole (P+L) as an initial endocrine-based therapy (approved March 2016), or with fulvestrant (P+F) following disease progression after prior endocrine therapy (approved May 2017). The Ibrance Real World Insights (IRIS) study () collected real-world outcomes data for palbociclib-treated patients in several countries, including Canada. Methods: This retrospective chart review included women with HR+/HER2− ABC/MBC receiving P+L or P+F in Canada. Physicians reviewed medical records for up to 14 patients, abstracting demographic and clinical characteristics, treatment patterns, and clinical outcomes. Progression-free rates (PFRs) and survival rates (SRs) at 6, 12, 18, and 24 months were estimated via Kaplan–Meier analysis. Results: Thirty-three physicians examined medical records for 247 patients (P+L, n = 214; P+F, n = 33). Median follow-up was 8.8 months for P+L and 7.0 months for P+F. Most patients were initiated on palbociclib 125 mg/d (P+L, 90.2%; P+F, 84.8%). Doses were reduced in 16.6% of P+L and 14.3% of P+F patients initiating palbociclib at 125 mg/d. The PFR for P+L was 90.3% at 12 months and 78.2% at 18 months; corresponding SRs were 95.6% and 93.0%. For P+F, 6-month PFR was 91.0%; 12-month SR was 100.0%. Conclusions: Dose reduction rates were low and PFR and SR were high in this Canadian real-world assessment of P+L and P+F treatments, suggesting that palbociclib combinations are well tolerated and effective. NCT03159195相似文献